Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

被引:27
|
作者
Nicolucci, Antonio [1 ]
Ceriello, Antonio [2 ,3 ]
Di Bartolo, Paolo [4 ]
Corcos, Antonella [5 ]
Orsini Federici, Marco [5 ]
机构
[1] Ctr Outcomes Res & Clin Epidemiol CORES, Pescara, Italy
[2] Inst Invest Biomed August Pi & Sunyer DIBAPS, Barcelona, Spain
[3] IRCCS MultiMed, Milan, Italy
[4] Internist Ravenna AUSL Romagna, Direttore UO Diabetol, Rete Clin Diabetol Aziendale Dipartimento, Ravenna, Italy
[5] Eli Lilly Italia SpA, Med Affairs Diabet, Sesto Fiorentino, Italy
关键词
Diabetes; Glycemic variability; Meta-analysis; Rapid-acting insulin analogues; Regular human insulin; BLOOD-GLUCOSE CONTROL; HUMAN SOLUBLE INSULIN; HUMAN PREMIX INSULIN; PLASMA-GLUCOSE; NOCTURNAL HYPOGLYCEMIA; INTENSIVE THERAPY; LISPRO INSULIN; NPH INSULIN; TYPE-1; ASPART;
D O I
10.1007/s13300-019-00732-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long- and short-term glycemic variability as measured by glycated haemoglobin (HbA1c) and pre- and postprandial glucose (PPG). Methods PubMed was searched for studies published between 1999 and 29 June 2016. Randomised controlled trials of patients with diabetes that assessed the effects of RAIAs or RHI on glycemic control, focusing on preprandial glucose, PPG and HbA1c, were included. Only studies that reported both means and standard deviations for those outcomes were analysed; from these data, weighted mean differences and 95% confidence intervals were generated to yield overall point estimates. The primary outcomes of the meta-analysis were the mean differences between RAIAs and RHI at the end of the study in PPG, preprandial glucose, and HbA1c. Results Twenty-seven studies (n = 7452) were included. The difference in PPG between RAIA- and RHI-treated patients was significant-in favour of RAIAs-in patients with type 1 diabetes (T1D) [- 22.2 mg/dL; 95% confidence interval (CI) - 27.4, - 17.0 mg/dL; P < 0.0001] but not in those with type 2 diabetes (T2D). For preprandial glucose, there was a non-significant trend favouring RHIs in T1D; no data were available for patients with T2D. In patients with T1D, the between-group difference in end-of-treatment (EOT) HbA1c favoured RAIAs (- 0.13%; 95% CI - 0.18, - 0.08%; P < 0.0001), but was not significant in patients with T2D. The main study limitations were the small number and heterogeneity of the included studies. Conclusions These results demonstrate that RAIAs are more effective at reducing PPG and improving HbA1c than RHIs in T1D. More data are required to assess the effect of these agents on glucose control in T2D. Plain Language Summary Plain language summary available for this article.
引用
收藏
页码:573 / 584
页数:12
相关论文
共 50 条
  • [41] RAPID-ACTING INSULIN ANALOGUES IN BASAL-BOLUS REGIMENS IN TYPE 1 DIABETES MELLITUS
    Garg, Satish
    Javier Ampudia-Blasco, Francisco
    Pfohl, Martin
    ENDOCRINE PRACTICE, 2010, 16 (03) : 486 - 505
  • [42] Safety of rapid-acting insulin analogues in pregnant women with diabetes in view of approved prescribing information
    Sieradzki, Jacek
    Stefanski, Adam
    CLINICAL DIABETOLOGY, 2012, 1 (06): : 233 - 238
  • [43] Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
    Monami, M.
    Marchionni, N.
    Mannucci, E.
    DIABETES OBESITY & METABOLISM, 2009, 11 (04): : 372 - 378
  • [44] Pharmacokinetics of a rapid-acting human insulin analogue, insulin aspart, in children and adolescents with type 1 diabetes
    Mortensen, H
    Olsen, B
    Li'ndholm, A
    DIABETES, 1999, 48 : A358 - A358
  • [45] Effects of the rapid-acting insulin analogue Insulin Aspart on postprandial glycaemic excursions in type 2 diabetes
    Thorsby, P
    Rosenfalck, AM
    Kjems, L
    Hanssen, KF
    Madsbad, S
    Birkeland, KI
    DIABETOLOGIA, 1999, 42 : A17 - A17
  • [46] Comparison of the Efficiency of Different Rapid-Acting Insulin Analogues used in Continuous Subcutaneous Insulin Infusion in the Glycaemic Control of Children with Type 1 Diabetes
    Mota, Silvia
    Pereira, Beatriz Belo
    Carvalho, Vasco
    Gomes, Maria Miguel
    Nascimento, Patricia
    Correia, Filipa
    Dias, Angela
    Martins, Sofia
    REVISTA PORTUGUESA DE ENDOCRINOLOGIA DIABETES E METABOLISMO, 2021, 16 (3-4) : 88 - 93
  • [47] Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis
    Kirsten Nørgaard
    Nithya Sukumar
    Snorri B. Rafnsson
    Ponnusamy Saravanan
    Diabetes Therapy, 2018, 9 : 891 - 917
  • [48] Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis
    Norgaard, Kirsten
    Sukumar, Nithya
    Rafnsson, Snorri B.
    Saravanan, Ponnusamy
    DIABETES THERAPY, 2018, 9 (03) : 891 - 917
  • [49] Resource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: The SWING study
    Reaney, Matthew
    Cypryk, Katarzyna
    Tentolouris, Nicholas
    Jecht, Michael
    Cleall, Simon
    Petzinger, Ute
    Koivisto, Veikko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) : 231 - 241
  • [50] EFFICACY AND SAFETY OF HUMAN INSULIN VERSUS ANIMAL INSULIN AMONG PATIENTS WITH DIABETES IN CHINA: A META-ANALYSIS
    Zhang, H. N.
    Wang, K.
    Yang, J.
    Liu, L.
    VALUE IN HEALTH, 2014, 17 (07) : A720 - A720